Buparlisib (BUP) or placebo (PBO) plus fulvestrant (FUL) in postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Overall survival (OS) results from BELLE-2, a randomized, phase III study

被引：0
|
作者：
Campone, Mario
Im, Seock-Ah
Iwata, Hiroji
Clemons, Mark
Ito, Yoshinori
Awada, Ahmad
Chia, Stephen
Jagiello-Gruszfeld, Agnieszka
Pistilli, Barbara
Tseng, Ling-Ming
Hurvitz, Sara
Masuda, Norikazu
Cortes, Javier
De laurentiis, Michele
Arteaga, Carlos L.
Jiang, Zefei
Jonat, Walter
Sellami, Dalila
El-Hashimy, Mona
Le Mouhaer, Sylvie
Sankaran, Banu
Bourdeau, Laurence
Baselga, Jose
机构：
[1] Ctr Rene Gauducheau, Inst Cancerol, Ouest Site, St Herblain, France
[2] Seoul Natl Univ, Coll Med, Seoul, South Korea
[3] Aichi Canc Ctr, Nagoya, Aichi, Japan
[4] Ottawa Hosp, Res Inst, Ottawa, ON, Canada
[5] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[6] Inst Jules Bordet, Brussels, Belgium
[7] BC Canc Agcy, Vancouver, BC, Canada
[8] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Warsaw, Poland
[9] Inst Gustave Roussy, Villejuif, France
[10] Taipei Vet Gen Hosp, Taipei, Taiwan
[11] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA
[12] Natl Hosp Org Osaka Natl Hosp, Osaka, Japan
[13] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[14] Fdn G Pascale, Ist Nazl Tumori, Naples, Italy
[15] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[16] PLA, Beijing Hosp 307, Beijing, Peoples R China
[17] Univ Hosp Schleswig Holstein, Kiel, Germany
[18] Novartis Pharmaceut, E Hanover, NJ USA
[19] Novartis Pharmaceut, Florham Pk, NJ USA
[20] Novartis Pharma SAS, Paris, France
[21] Novartis Inst BioMed Res, Cambridge, MA USA
[22] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD5-12
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
    Campone, Mario
    Im, Seock-Ah
    Iwata, Hiroji
    Clemons, Mark
    Ito, Yoshinori
    Awada, Ahmad
    Chia, Stephen
    Jagiello-Gruszfeld, Agnieszka
    Pistilli, Barbara
    Tseng, Ling-Ming
    Hurvitz, Sara
    Masuda, Norikazu
    Cortes, Javier
    De Laurentiis, Michele
    Arteaga, Carlos L.
    Jiang, Zefei
    Jonat, Walter
    Le Mouhaer, Sylvie
    Sankaran, Banu
    Bourdeau, Laurence
    El-Hashimy, Mona
    Sellami, Dalila
    Baselga, Jose
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : 147 - 154
  • [2] Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) + ribociclib (RIB)
    Slamon, D. J.
    Neven, P.
    Chia, S.
    Fasching, P. A.
    De Laurentiis, M.
    Im, S-A.
    Petrakova, K.
    Bianchi, G. V.
    Esteva, F. J.
    Martin, M.
    Nusch, A.
    Sonke, G. S.
    De la Cruz-Merino, L.
    Beck, J. T.
    Pivot, X.
    Sondhi, M.
    Wang, Y.
    Chakravartty, A.
    Rodriguez-Lorenc, K.
    Jerusalem, G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [3] Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) plus fulvestrant (FUL) for hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2e) advanced breast cancer (ABC)
    Andre, F.
    Ciruelos, E. M.
    Juric, D.
    Loibl, S.
    Campone, M.
    Mayer, I.
    Rubovszky, G.
    Yamashita, T.
    Kaufman, B.
    Lu, Y-S.
    Inoue, K.
    Papai, Z.
    Takahashi, M.
    Ghaznawi, F.
    Mills, D.
    Kaper, M.
    Miller, M.
    Conte, P. F.
    Iwata, H.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S1150 - S1151
  • [4] Overall survival (OS) with palbociclib (PAL) plus fulvestrant (FUL) in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Updated analyses from PALOMA-3.
    Cristofanilli, Massimo
    Rugo, Hope S.
    Im, Seock-Ah
    Slamon, Dennis J.
    Harbeck, Nadia
    Bondarenko, Igor
    Masuda, Norikazu
    Colleoni, Marco
    DeMichele, Angela
    Iwata, Sherene Loi Hiroji
    O'Leary, Ben
    Bananis, Eustratios
    Liu, Yuan
    Huang, Xin
    Kim, Sindy
    Lechuga, Mariajose
    Turner, Nicholas C.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Analyses from PALOMA-3
    Cristofanilli, M.
    Slamon, D. J.
    Ro, J.
    Bondarenko, I.
    Im, S-A.
    Masuda, N.
    Colleoni, M.
    DeMichele, A.
    Loi, S.
    Verma, S.
    Iwata, H.
    Harbeck, N.
    Loibl, S.
    Andre, F.
    Theall, K. Puyana
    Huang, X.
    Giorgetti, C.
    Bartlett, C. Huang
    Turner, N. C.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] Ribociclib (RIB) plus fulvestrant (FUL) in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-3 biomarker analyses
    Neven, P.
    Petrakova, K.
    Bianchi, G. V.
    Merino, L. De la Cruz
    Jerusalem, G.
    Beck, J. T.
    Sonke, G. S.
    Chia, S.
    Brucker, S.
    Wang, Y.
    He, W.
    Lorenc, K. Rodriguez
    Su, F.
    Im, S-A.
    ANNALS OF ONCOLOGY, 2018, 29 : 113 - +
  • [7] COST-EFFECTIVENESS OF RIBOCILIB PLUS FULVESTRANT (R plus F) VS FULVESTRANT (FUL) IN HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE
    Stellato, D.
    Thabane, M.
    Chandiwana, D.
    Lanoue, B.
    Delea, T. E.
    VALUE IN HEALTH, 2020, 23 : S45 - S45
  • [8] ECONOMIC ANALYSIS OF COMBINATION THERAPY WITH ALPELISIB AND FULVESTRANT FOR TREATMENT OF HORMONE RECEPTOR-POSITIVE (HR plus ) AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER
    Delevry, D.
    Le, Q. A.
    VALUE IN HEALTH, 2020, 23 : S32 - S33
  • [9] Patients' preferences for postmenopausal hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer treatments in Japan
    Omori, Y.
    Enatsu, S.
    Cai, Z.
    Ishiguro, H.
    CANCER RESEARCH, 2019, 79 (04)
  • [10] Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
    Baselga, Jose
    Im, Seock-Ah
    Iwata, Hiroji
    Cortes, Javier
    De laurentiis, Michele
    Jiang, Zefei
    Arteaga, Carlos L.
    Jonat, Walter
    Clemons, Mark
    Ito, Yoshinori
    Awada, Ahmad
    Chia, Stephen
    Jagiello-Gruszfeld, Agnieszka
    Pistilli, Barbara
    Tseng, Ling-Ming
    Hurvitz, Sara
    Masuda, Norikazu
    Takahashi, Masato
    Vuylsteke, Peter
    Hachemi, Soulef
    Dharan, Bharani
    Di Tomaso, Emmanuelle
    Urban, Patrick
    Massacesi, Cristian
    Campone, Mario
    LANCET ONCOLOGY, 2017, 18 (07): : 904 - 916
12345